ERBB2 and neoplasm: Hedge et al. [255] created dual-targeting CAR-T (biCAR-T) cells targeting both HER2 and IL-13Rα2, which could efficiently recognize and kill either HER2 or IL-13Rα2-positive tumor cells, improving the survival while being more sustainable.